SGLT-2 Inhibitors and Lower Urinary Tract Symptoms

N/AActive Not RecruitingNCT07716774

Marmara University40 enrolled

Overview

This prospective observational study aims to evaluate the effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on lower urinary tract symptoms (LUTS) in patients with type 2 diabetes mellitus. Patients who are newly initiated on SGLT-2 inhibitor therapy as part of routine clinical care will be evaluated at baseline and after one month using a 3-day bladder diary and the Overactive Bladder Questionnaire (OAB-v8). Changes in storage symptoms, including urinary frequency, urgency, nocturia, and urinary incontinence, will be assessed to better characterize the impact of SGLT-2 inhibitor therapy on LUTS.

Study Type

OBSERVATIONAL

Enrollment

Conditions

SGLT2 Inhibitors Lower Urinary Track Symptoms Overactive Bladder

Interventions

No Intervention: Observational Cohort

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Adults (≥18 years of age) * Patients with type 2 diabetes mellitus newly initiated on oral SGLT-2 inhibitor therapy Exclusion Criteria: * Age \<18 years * Patients with insulin-dependent diabetes mellitus (IDDM) * Patients with diabetes-related complications (e.g., diabetic nephropathy, retinopathy, or vasculopathy) * Patients receiving anticholinergic or α-blocker therapy for lower urinary tract symptoms (LUTS) * History of urinary incontinence surgery (including any surgical procedure involving the urethral sphincter, bladder neck, pelvic floor, or pelvic nerves) * Patients with urinary tract infection (UTI)

SGLT-2 Inhibitors and Lower Urinary Tract Symptoms

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes